HKU Scholars Hub: Browsing DSpace

Browsing by Author Ma, XL

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 8 of 8

	Title	Author(s)	Issue Date	Views
	Continued therapy with ABI-H0731+NRTI results in sequential reduction/loss of HBV DNA, HBV RNA, HBeAg, HBcrAg and HBsAg in HBeAg positive patients Proceeding/Conference:Hepatology	Sulkowski, MS Agarwal, K Fung, SK Yuen, RMF Ma, XL Lalezari, JP Nguyen, TT Bae, HS Schiff, ER Hassanein, T Hann, HWL Elkhashab, M Dieterich, DT Kwo, PY Nahass, R Ramji, A Park, JS Ravendhran, N Chan, S Weilert, F Han, SHB Ayoub, WS Gane, EJ Jacobson, IM Bennett, M Bonacini, M Zayed, H Alves, K Huey, V Huang, Q Ruby, E Qiang, DM Knox, S Colonno, R	2019	54
	Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naïve patients with HBeAg positive chronic hepatitis B. Poster Presentation (SAT866) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology	Sulkowski, MS Fung, SK Ma, XL Nguyen, TT Schiff, ER Hann, H-W L Dieterich, DT Nahass, RG Park, JS Chen, S Han, S-H B Gane, EJ Bennett, M Yan, R Liu, JM Ma, J Knox, SJ Stamm, LM Bonacini, M Jacobson, IM Ayoub, WS Weilert, F Ravendhran, N Ramji, A Kwo, PY Elkhashab, M Hassanein, T Bae, HS Lalezari, K Yuen, RMF	2022	2
	HBV PGRNA and DNA both rebound immediately following discontinuation of the core inhibitor vebicorvir despite continued nrti treatment in patients with HBeAg positive chronic hepatitis B virus infection: findings from a phase 2 open label study Proceeding/Conference:Oral presentation at the AASLD The Liver Meeting, November 12-15. 2021. Hepatology	Yuen, RMF Ma, XL Hassanein, TI Kwo, PY Ma, J Li, L Kitrinos, K Knox, SJ Stamm, LM Bae, H Sulkowski, MS Elkhashab, M Agarwal, K	2021
	Hyperglycemia-Induced Protein Kinase Cβ2 Activation Induces Diastolic Cardiac Dysfunction in Diabetic Rats by Impairing Caveolin-3 Expression and Akt/eNOS Signaling Journal:Diabetes	Lei, S Li, H Xu, J Liu, Y Gao, X Wang, JJ Ng, JKF Lau, WB Ma, XL Rodrigues, B Irwin, MG Xia, Z	2013	37
	Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients Proceeding/Conference:Journal of Hepatology	Ma, XL Lalezari, J Nguyuen, T Bae, Ho Schiff, ER Fung, S Yuen, RMF Hassanein, T Hann, HW Elkhashab, M Dieterich, D Sulkowski, M Kwo, P Nahass, R Agarwal, K Ramji, A Park, J Ravendhran, N Chan, S Weilert, F Han, SH Ayoub, W Gane, E Jacobson, I Bennett, M Huang, Q Yan, R Huey, V Ruby, E Liaw, S Colonno, R Lopatin, U	2019	74
	Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection Journal:Journal of Hepatology	Sulkowski, MS Agarwal, K Ma, XL Nguyen, TT Schiff, ER Hann, H-W L Dieterich, DT Nahass, RG Park, JS Chan, S Han, S-H B Gane, EJ Bennett, M Alves, K Evanchik, M Yan, R Huang, Q Lopatin, U Colonno, R Ma, J Knox, SJ Stamm, LM Bonacini, M Jacobson, IM Ayoub, WS Weilert, F Ravendhran, N Ramj, A Kwo, PY Elkhashab, M Hassanein, T Bae, HS Lalezari, JP Fung, SK Yuen, RMF	2022
	Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection Journal:Journal of Hepatology	Yuen, RMF Agarwal, K Ma, XL Nguyen, TT Schiff, ER Hann, H-WL Dieterich, DT Nahass, RT Park, JS Chan, S Han, S-H B Gane, EJ Bennett, M Alves, K Evanchik, M Yan, R Huang, Q Lopatin, U Colonno, R Ma, J Knox, SJ Stamm, LM Bonacini, M Jacobson, IM Ayoub, WS Weilert, F Ravendhran, N Ramji, A Kwo, PY Elkhashab, M Hassanein, T Bae, HS Lalezari, JP Fung, SK Sulkowski, MS	2022
	The teaching of Chinese as a second or foreign language: a systematic review of the literature 2005–2015 Journal:Journal of Multilingual & Multicultural Development	Ma, XL Gong, Y Gao, AX Xiang, YQ	2017	80

Showing results 1 to 8 of 8